These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 32656741)

  • 21. DEK::AFF2 Fusion Carcinomas of Head and Neck.
    Ruangritchankul K; Sandison A
    Adv Anat Pathol; 2023 Mar; 30(2):86-94. PubMed ID: 36221219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The miR-1204 regulates apoptosis in NSCLC cells by targeting DEK.
    Qian Z; Yang J; Liu H; Yin Y; Hou L; Hu H
    Folia Histochem Cytobiol; 2019; 57(2):64-73. PubMed ID: 31246264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
    Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
    Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DEK promotes the proliferation and invasion of lung cancers and indicates poor prognosis in lung adenocarcinomas.
    Yang MQ; Bai LL; Lei L; Zheng YW; Wang Z; Li ZH; Liu CC; Huang WJ; Xu HT
    Oncol Rep; 2020 Apr; 43(4):1338-1348. PubMed ID: 32020224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Middle Ear and Temporal Bone Nonkeratinizing Squamous Cell Carcinomas With DEK-AFF2 Fusion: An Emerging Entity.
    Todorovic E; Truong T; Eskander A; Lin V; Swanson D; Dickson BC; Weinreb I
    Am J Surg Pathol; 2020 Sep; 44(9):1244-1250. PubMed ID: 32366754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.
    Campregher PV; Halley NDS; Vieira GA; Fernandes JF; Velloso EDRP; Ali S; Mughal T; Miller V; Mangueira CLP; Odone V; Hamerschlak N
    Leuk Lymphoma; 2017 Dec; 58(12):2969-2972. PubMed ID: 28509585
    [No Abstract]   [Full Text] [Related]  

  • 27. Bacterial Growth Inhibition Screen (BGIS) identifies a loss-of-function mutant of the DEK oncogene, indicating DNA modulating activities of DEK in chromatin.
    Guo H; Prell M; Königs H; Xu N; Waldmann T; Hermans-Sachweh B; Ferrando-May E; Lüscher B; Kappes F
    FEBS Lett; 2021 May; 595(10):1438-1453. PubMed ID: 33686684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML).
    Logan GE; Mor-Vaknin N; Braunschweig T; Jost E; Schmidt PV; Markovitz DM; Mills KI; Kappes F; Percy MJ
    Blood Cells Mol Dis; 2015 Jan; 54(1):123-31. PubMed ID: 25128083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DEK-AFF2 Carcinoma of the Sinonasal Region and Skull Base: Detailed Clinicopathologic Characterization of a Distinctive Entity.
    Rooper LM; Agaimy A; Dickson BC; Dueber JC; Eberhart CG; Gagan J; Hartmann A; Khararjian A; London NR; MacMillan CM; Palsgrove DN; Nix JS; Sandison A; Stoehr R; Truong T; Weinreb I; Bishop JA
    Am J Surg Pathol; 2021 Dec; 45(12):1682-1693. PubMed ID: 34049316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.
    Sandahl JD; Coenen EA; Forestier E; Harbott J; Johansson B; Kerndrup G; Adachi S; Auvrignon A; Beverloo HB; Cayuela JM; Chilton L; Fornerod M; de Haas V; Harrison CJ; Inaba H; Kaspers GJ; Liang DC; Locatelli F; Masetti R; Perot C; Raimondi SC; Reinhardt K; Tomizawa D; von Neuhoff N; Zecca M; Zwaan CM; van den Heuvel-Eibrink MM; Hasle H
    Haematologica; 2014 May; 99(5):865-72. PubMed ID: 24441146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epithelial‑mesenchymal transition in colorectal carcinoma cells is mediated by DEK/IMP3.
    You S; Guan Y; Li W
    Mol Med Rep; 2018 Jan; 17(1):1065-1070. PubMed ID: 29115492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [High-risk acute myeloid leukemia with DEK-NUP214 rearrangement and eyelid infiltration: a case report].
    Li XZ; Huang R; Gao TQ; Xie XW; Zhou YQ; Zeng QL; Liu JD; Gu XK; Liu ZH
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):512. PubMed ID: 38964929
    [No Abstract]   [Full Text] [Related]  

  • 33. DEK Expression is controlled by E2F and deregulated in diverse tumor types.
    Carro MS; Spiga FM; Quarto M; Di Ninni V; Volorio S; Alcalay M; Müller H
    Cell Cycle; 2006 Jun; 5(11):1202-7. PubMed ID: 16721057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Relationship between DEK oncogene expression and oral squamous cell carcinoma].
    Wang X; Huang SH; Yu LQ; Liu J; Diao Y; Sun CF
    Shanghai Kou Qiang Yi Xue; 2014 Feb; 23(1):75-9. PubMed ID: 24608617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p21-activated kinase 2 binds to transcription factor SOX2 and up-regulates DEK to promote the progression of lung squamous cell carcinoma.
    Xie S; Wan X; Chen S; Hu Y; Liu X
    Lab Invest; 2022 Oct; 102(10):1109-1120. PubMed ID: 35821094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysis.
    Matrka MC; Watanabe M; Muraleedharan R; Lambert PF; Lane AN; Romick-Rosendale LE; Wells SI
    PLoS One; 2017; 12(5):e0177952. PubMed ID: 28558019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nuclear DEK preserves hematopoietic stem cells potential via NCoR1/HDAC3-Akt1/2-mTOR axis.
    Chen Z; Huo D; Li L; Liu Z; Li Z; Xu S; Huang Y; Wu W; Zhou C; Liu Y; Kuang M; Wu F; Li H; Qian P; Song G; Wu X; Chen J; Hou Y
    J Exp Med; 2021 May; 218(5):. PubMed ID: 33755722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DEK depletion negatively regulates Rho/ROCK/MLC pathway in non-small cell lung cancer.
    Wang J; Sun L; Yang M; Luo W; Gao Y; Liu Z; Qiu X; Wang E
    J Histochem Cytochem; 2013 Jul; 61(7):510-21. PubMed ID: 23571382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival.
    Hacker KE; Bolland DE; Tan L; Saha AK; Niknafs YS; Markovitz DM; McLean K
    Neoplasia; 2018 Dec; 20(12):1209-1218. PubMed ID: 30412857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Melanoma proliferation and chemoresistance controlled by the DEK oncogene.
    Khodadoust MS; Verhaegen M; Kappes F; Riveiro-Falkenbach E; Cigudosa JC; Kim DS; Chinnaiyan AM; Markovitz DM; Soengas MS
    Cancer Res; 2009 Aug; 69(16):6405-13. PubMed ID: 19679545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.